Verona Pharma Plc Stock Current Valuation
| VRNA Stock | USD 38.81 0.95 2.51% |
Valuation analysis of Verona Pharma PLC helps investors to measure Verona Pharma's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. As of November 25, 2024, Enterprise Value Over EBITDA is expected to decline to -27.12. In addition to that, Enterprise Value Multiple is expected to decline to -27.12. Fundamental drivers impacting Verona Pharma's valuation include:
Price Book 24.3378 | Enterprise Value 3 B | Enterprise Value Ebitda (20.89) | Price Sales 564.6993 | Enterprise Value Revenue 526.6959 |
Fairly Valued
Today
Please note that Verona Pharma's price fluctuation is very steady at this time. Calculation of the real value of Verona Pharma PLC is based on 3 months time horizon. Increasing Verona Pharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Verona Pharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Verona Stock. However, Verona Pharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 38.81 | Real 37.85 | Target 33.14 | Hype 39.19 | Naive 39.08 |
The real value of Verona Stock, also known as its intrinsic value, is the underlying worth of Verona Pharma PLC Company, which is reflected in its stock price. It is based on Verona Pharma's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Verona Pharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Verona Pharma PLC helps investors to forecast how Verona stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Verona Pharma more accurately as focusing exclusively on Verona Pharma's fundamentals will not take into account other important factors: Verona Pharma PLC Company Current Valuation Analysis
Verona Pharma's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Verona Pharma Current Valuation | 2.96 B |
Most of Verona Pharma's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Verona Pharma PLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Verona Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Verona Pharma is extremely important. It helps to project a fair market value of Verona Stock properly, considering its historical fundamentals such as Current Valuation. Since Verona Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Verona Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Verona Pharma's interrelated accounts and indicators.
Click cells to compare fundamentals
Verona Current Valuation Historical Pattern
Today, most investors in Verona Pharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Verona Pharma's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Verona Pharma current valuation as a starting point in their analysis.
Verona Pharma Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Verona Pharma PLC has a Current Valuation of 2.96 B. This is 79.38% lower than that of the Pharmaceuticals sector and 36.24% lower than that of the Health Care industry. The current valuation for all United States stocks is 82.18% higher than that of the company.
Verona Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Verona Pharma's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Verona Pharma could also be used in its relative valuation, which is a method of valuing Verona Pharma by comparing valuation metrics of similar companies.Verona Pharma is currently under evaluation in current valuation category among its peers.
Verona Pharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of Verona Pharma from analyzing Verona Pharma's financial statements. These drivers represent accounts that assess Verona Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Verona Pharma's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 993.9M | 57.1M | 397.5M | 1.7B | 1.6B | 3.0B | |
| Enterprise Value | 968.8M | 28.3M | 254.9M | 1.5B | 1.4B | 1.3B |
Verona Pharma ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Verona Pharma's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Verona Pharma's managers, analysts, and investors.Environmental | Governance | Social |
Verona Fundamentals
| Return On Equity | -0.78 | ||||
| Return On Asset | -0.28 | ||||
| Operating Margin | (6.94) % | ||||
| Current Valuation | 2.96 B | ||||
| Shares Outstanding | 81.83 M | ||||
| Shares Owned By Insiders | 4.13 % | ||||
| Shares Owned By Institutions | 89.40 % | ||||
| Number Of Shares Shorted | 7.52 M | ||||
| Price To Earning | (9.15) X | ||||
| Price To Book | 24.34 X | ||||
| Price To Sales | 564.70 X | ||||
| Revenue | 458 K | ||||
| Gross Profit | 112 K | ||||
| EBITDA | (52.47 M) | ||||
| Net Income | (54.58 M) | ||||
| Cash And Equivalents | 111.51 M | ||||
| Cash Per Share | 1.83 X | ||||
| Total Debt | 51.33 M | ||||
| Debt To Equity | 0.05 % | ||||
| Current Ratio | 3.57 X | ||||
| Book Value Per Share | 1.59 X | ||||
| Cash Flow From Operations | (50.22 M) | ||||
| Short Ratio | 8.04 X | ||||
| Earnings Per Share | (2.00) X | ||||
| Target Price | 46.57 | ||||
| Number Of Employees | 79 | ||||
| Beta | 0.42 | ||||
| Market Capitalization | 3.18 B | ||||
| Total Asset | 308.12 M | ||||
| Retained Earnings | (388.43 M) | ||||
| Working Capital | 281.02 M | ||||
| Net Asset | 308.12 M |
About Verona Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Verona Pharma PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Verona Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Verona Pharma PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Verona Pharma PLC offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Verona Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Verona Pharma Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Verona Pharma Plc Stock:Check out Verona Pharma Piotroski F Score and Verona Pharma Altman Z Score analysis. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Verona Pharma. If investors know Verona will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Verona Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.00) | Revenue Per Share 0.07 | Return On Assets (0.28) | Return On Equity (0.78) |
The market value of Verona Pharma PLC is measured differently than its book value, which is the value of Verona that is recorded on the company's balance sheet. Investors also form their own opinion of Verona Pharma's value that differs from its market value or its book value, called intrinsic value, which is Verona Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Verona Pharma's market value can be influenced by many factors that don't directly affect Verona Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Verona Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Verona Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Verona Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.